Your session is about to expire
← Back to Search
Acalabrutinib + Venetoclax ± Obinutuzumab for Chronic Lymphocytic Leukemia
Study Summary
This trial is testing a new combination therapy for leukemia/lymphoma that has returned or is resistant to treatment. The new therapy includes a targeted drug and an immunotherapy drug.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have an autoimmune condition needing high-dose steroids.You have had serious allergic reactions to certain types of medications made from animals or you are known to be allergic to certain animal products.I do not have an active hepatitis B infection, or I am vaccinated against it.My white blood cell count is healthy, not due to cancer in my bone marrow.I haven't taken strong CYP3A affecting drugs in the last 7 days.I have been treated with both BTK and BCL2 inhibitors.My condition did not improve after at least one treatment.I have not eaten grapefruit, Seville oranges, or star fruit in the last 3 days.I do not have serious heart problems like recent heart attacks or uncontrolled heart rhythm issues.I am over 65 or have a high-risk feature in my cancer.I can take care of myself and am up and about more than half of the day.I haven't had cancer, except for certain skin cancers or early-stage cervical or breast cancer, in the last 2 years.I am currently taking warfarin.I have not had a stroke or brain bleed in the last 6 months.I am HIV positive and on medication.You have a serious medical or mental health condition that could make participating in the study risky or affect the results.I am willing to change my acid reflux medication before starting treatment.I cannot take medications by mouth due to a digestive condition.I have active hepatitis C confirmed by a PCR test.I haven't had major treatments or live vaccines in the last 3 weeks, unless my disease is quickly getting worse.I am not pregnant, will use birth control during the study, and for some time after.My platelet count is above 30,000 and I haven't had a transfusion in the last 2 weeks.I have been diagnosed with CLL/SLL and need treatment according to 2018 guidelines.I do not have any ongoing serious infections.My kidney function, measured by creatinine clearance, is good.
- Group 1: Arm II (acalabrutinib, venetoclax, early obinutuzumab)
- Group 2: Arm I (acalabrutinib, venetoclax, obinutuzumab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What conditions is Obinutuzumab primarily utilized for?
"Obinutuzumab is a common recommendation for amino acid supplementation. It has also been found to be effective at treating acute coryza, mantle cell lymphoma after one prior therapy, and refractory follicular lymphoma."
Has Obinutuzumab been greenlit by the FDA?
"The safety of Obinutuzumab was rated as a 2 on our scale, signifying that there is some clinical data demonstrating its security but no evidence to suggest it works."
Is this medical experiment actively searching for participants?
"According to clinicaltrials.gov, this research is actively searching for participants. The trial was first published on July 29th 2020 and most recently updated August 17th 2022."
How many individuals are participating in this experiment?
"Affirmative. According to clinicaltrials.gov, this trial is continuing to accept new participants since its posting date of July 29th 2020 and most recent update on August 17th 2022. 168 people are required at one particular medical site for the study to reach completion."
Is this the inaugural trial of its kind?
"Currently, there are 371 live studies concerning Obinutuzumab spread out across 56 nations and 1772 cities. Baxter Healthcare Corporation's trail in 2007 was the first to explore its effects; it concluded Phase 4 drug approval with 4640 participants. In total, since then 161 trials have already reached completion."
Have there been any previous investigations involving Obinutuzumab?
"As of now, 371 clinical trials are being conducted to assess the effectiveness of Obinutuzumab. 46 of these active studies have become Phase 3 trials and they span 17142 sites across Edmonton, Alberta."
Share this study with friends
Copy Link
Messenger